Oncology Clinical Trials in Palo Alto, CA
As of August 2026, 114 paid clinical trials are recruiting for Oncology in Palo Alto, California. Compensation typically covers time, travel, and study visits, and many studies also include study-related medical care at no cost.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
Newly added in Palo Alto
Posted to ClinicalTrials.gov within the last 60 days — these studies are just starting to recruit.
Algorithm-enabled Goals of Care Communication
116 clinical trials for Oncology
·Clear filters·Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
FOG-001 in Locally Advanced or Metastatic Solid Tumors
A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer
Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)
Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
Galleri® in the Medicare Population.
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)
CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
A Study of PHST001 in Advanced Solid Tumors
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
SPEARHEAD-3 Pediatric Study
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With REGN5678 for Adult Participants With Advanced Prostate Cancer
Study of Denikitug (GS-1811) Given Alone or With Zimberelimab in Adults With Advanced Solid Tumors
Top Research Study Locations in Palo Alto
Researchers run research studies in Palo Alto, CA at 25 active sites. The clinics below currently host the largest number of recruiting studies — each name is followed by the conditions they focus on most.
| Site | Specializes in | Active trials |
|---|---|---|
| Stanford University | Myelodysplastic Syndromes, Amblyopia, Healthy | 160 |
| Stanford Cancer Institute Palo Alto | Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8 | 33 |
| Stanford University Medical Center | Cystic Fibrosis, Prostate Cancer, Acute Lymphoblastic Leukemia | 28 |
| VA Palo Alto Health Care System, Palo Alto, CA | Cancer, Heart Failure, Homelessness | 28 |
| Lucile Packard Children's Hospital | Hematologic Diseases, Heart Failure, Pneumonia | 24 |
| Lucile Packard Children's Hospital Stanford University | Osteosarcoma, Acute Myeloid Leukemia, B Acute Lymphoblastic Leukemia | 22 |
| Stanford University School of Medicine | Epilepsy, Health Behavior, Lifestyle Intervention | 21 |
| VA Palo Alto Health Care System | Alcohol Use Disorder, Advanced Malignant Solid Neoplasm, Alcohol Abuse | 20 |
| Stanford Cancer Center | Breast Neoplasms, Leukemia, Myeloid, Acute, Advanced Breast Cancer | 20 |
| Stanford Cancer Institute | Chronic Lymphocytic Leukemia, Breast Cancer, Small Lymphocytic Lymphoma | 18 |
| Lucile Packard Children's Hospital Stanford | Surgery, Acute Kidney Injury, Acute Kidney Injury Due to Sepsis | 16 |
| Palo Alto Medical Foundation Health Care | Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, HER2-Negative Breast Carcinoma | 15 |
| Stanford | Epilepsy, Epilepsy (Treatment Refractory), AML (Acute Myelogenous Leukemia) | 11 |
| Stanford Neuroscience Health Center | Alzheimer's Disease, Amyloid, Becker Muscular Dystrophy | 9 |
| Stanford Hospital | Drug Liking, Angina Pectoris, Autoimmune | 7 |
| Byers Eye Institute | Glaucoma, Eye Disorders, Astigmatism | 6 |
| Byers Eye Institute at Stanford University | Glaucoma, Blindness, Eye Cancer | 6 |
| Stanford Health Care | Cholecystitis, Cholecystitis, Chronic, Chronic Calculous Cholecystitis | 6 |
| Stanford Medical Center | AML - Acute Myeloid Leukemia, Alzheimer Disease, Chronic Myeloid Leukemia | 6 |
| Stanford Women's Cancer Center | Breast Cancer, Advanced Breast Cancer, Breast Neoplasms | 6 |
| Lucille Packard Children's Hospital | Anesthesia, Local, Intubation Complication, Obesity, Morbid | 5 |
| Stanford Medicine | B-cell Malignancy, Chronic Lymphocytic Leukemia, Diabetes Mellitus, Type 1 | 5 |
| Stanford University, School of Medicine | Liver Cancer, Adult, Lung Carcinoma, Lymphoma | 5 |
| Stanford Hospital and Clinics | Implant Based Breast Reconstruction, Chronic Ischemic Left Ventricular Dysfunction, Lymphedema Arm | 4 |
| Lucile Packard Children's Hospital at Stanford | Cardiac MRI, Cell Free DNA, Congenital Heart Disease | 3 |
Active & Upcoming Studies in Palo Alto (2026)
Recruiting trials in Palo Alto grouped by therapeutic area, drawn from ClinicalTrials.gov. Each bucket shows the most recent example studies.
Cancer & tumors (192 active studies)
- The Effects of Cannabis on Post Operative Recovery After Radical Cystectomy · EARLY_Phase 1 · Stanford University
- End Hole vs. Pressure-Modulated Delivery of Y-90 Resin Microspheres to Liver Metastases. · Stanford University
Neurology & pain (41 active studies)
- Empowered Relief for Caregivers · Stanford University
- Smartshoes for Freezing of Gait in Parkinson's Disease · Stanford University
Cardiovascular (35 active studies)
- The Effectiveness of Patch-Based Screening for Pre-Symptomatic Atrial Fibrillation to Improve Patient Outcome · VA Office of Research and Development
- Personalized Blood Transfusion Protocol for Cardiac Patients · Yan Mia Min
Mental health & behavior (18 active studies)
- Rapid Acceleration Process for Intensive Treatment of PTSD in 5 Days · Phase 3 · VA Office of Research and Development
- Employing Peer Outreach and Whole Health in Recovery for Homeless-Experienced Veterans · VA Office of Research and Development
Eye & vision (16 active studies)
- Topical Insulin for Glaucoma (TING2) · Phase 1, Phase 2 · Stanford University
- Phase 1 Study of C.001 in Retinal Degeneration · Phase 1 · Cellio Therapeutics Inc
Diabetes & metabolic (15 active studies)
- Simplifying Diet Tracking in a Digital Weight Loss Intervention · Stanford University
- Using a Personalized Decision Support Tool to Help People With Type 1 Diabetes Manage Exercise · Stanford University
Pediatric (14 active studies)
- Supraglottic Airway for Resuscitation Trial · Children's Hospital of Philadelphia
- GPC2-CAR T Cell Therapy for Relapsed or Refractory Medulloblastoma in Children and Young Adults · Phase 1 · Stanford University
Vaccines (7 active studies)
- Microbial and Cytokine Signatures in Long COVID Patients · Palo Alto Medical Foundation
- A Phase 3 Study of Revaccination in Subsequent Pregnancies With Bivalent RSV Vaccine and Duration of Protection of a Single Dose · Phase 3 · Pfizer
HIV / STI (1 active study)
- Study of AHB-137 in Chronic Hepatitis B (CHB) Participants in North America and Europe Regions · Phase 2 · AusperBio Therapeutics Inc.
Common conditions studied in Palo Alto
- Cancer (9 active studies)
- Breast Cancer (8 active studies)
- Heart Failure (8 active studies)
- Chronic Lymphocytic Leukemia (7 active studies)
- Epilepsy (7 active studies)
- Acute Myeloid Leukemia (6 active studies)
Leading research sponsors in Palo Alto
- Stanford University
- VA Office of Research and Development
- National Cancer Institute (NCI)
- Children's Oncology Group
- NRG Oncology
Frequently asked questions
How many paid clinical trials are currently recruiting in Palo Alto?
There are approximately 655 recruiting clinical trials in Palo Alto, California listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Palo Alto pay participants?
Most recruiting trials in Palo Alto compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Palo Alto?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Palo Alto?
The most common conditions under active study in Palo Alto include Cancer (9), Breast Cancer (8), Heart Failure (8), Chronic Lymphocytic Leukemia (7), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Palo Alto?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Palo Alto on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Palo Alto?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Palo Alto?
Recruiting research sites in Palo Alto include Stanford University, Stanford Cancer Institute Palo Alto, Stanford University Medical Center, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Palo Alto right now?
The largest active categories in Palo Alto are Cancer & tumors (192), Neurology & pain (41), Cardiovascular (35). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.